/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive data from the Phase 3 multicenter, placebo-controlled, double-blind,...

Related Keywords

France , Dublin , Ireland , Japan , United States , Japanese , American , Dauvilliersy Arnulf , Kristin Bhavnani , Andrean Flynn , Rob Iannone , Yves Dauvilliers , American Psychiatric Association , Jazz Pharmaceuticals Inc , International Classification Of Sleep Disorders , Department Of Neurology , Jazz Pharmaceuticals , Drug Administration , Head Of Global Corporate Affairs , United States Drug Enforcement Agency , Office Of Orphan Product Development , Us Drug Enforcement Agency , Nasdaq , American Academy Of Sleep Medicine , Health Problem , Prnewswire Jazz Pharmaceuticals , Wake Disorders Centre , Epworth Sleepiness Scale , Idiopathic Hypersomnia Severity Scale , Gui De Chauliac Hospital , Orphan Drug Exclusivity , Orphan Drug Designation , Patient Global Impression , Clinical Global Impression , Functional Outcomes , Sleep Questionnaire , Work Productivity , Activity Impairment Questionnaire , Specific Health Problem , Boxed Warning , Prescribing Information , Medication Guide , Orphan Product Development , Enforcement Agency , Global Corporate Affairs , Palo Alto , International Classification , Third Edition , Idiopathic Hypersomnia Severity , States Drug Enforcement , Accessed December , Statistical Manual , Fifth Edition , Opin Investig , Jazz Pharmaceuticals Plc , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , Biotechnology , Clinical Trials Amp Medical Discoveries ,